Simulations Plus, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Simulations Plus, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Aug 31, 2023 | $59.58M | Oct 27, 2023 |
| FY2023 | Aug 31, 2022 | $53.91M | Oct 27, 2023 |
| FY2021 | Aug 31, 2021 | $9.84M | Oct 27, 2021 |
| FY2021 | May 31, 2021 | $12.78M | Oct 27, 2021 |
| FY2021 | Feb 28, 2021 | $13.15M | Oct 27, 2021 |
| FY2021 | Nov 30, 2020 | $10.70M | Oct 27, 2021 |
| FY2021 | Aug 31, 2020 | $9.54M | Oct 27, 2021 |
| FY2021 | May 31, 2020 | $12.30M | Oct 27, 2021 |
| FY2021 | Feb 29, 2020 | $10.35M | Oct 27, 2021 |
| FY2021 | Nov 30, 2019 | $9.40M | Oct 27, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $79.18M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $70.01M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $59.58M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $53.91M | Oct 30, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Aug 31, 2014 | $11.46M | Nov 28, 2014 |
| FY2014 | Aug 31, 2013 | $10.07M | Nov 28, 2014 |
| FY2013 | Aug 31, 2012 | $9.45M | Nov 18, 2013 |
| FY2012 | Aug 31, 2011 | $8.74M | Nov 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $46.22M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $43.15M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $47.95M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $43.08M | Oct 30, 2024 |
| FY2021 | Aug 31, 2021 | $7.06M | Oct 27, 2021 |
| FY2021 | May 31, 2021 | $10.31M | Oct 27, 2021 |
| FY2021 | Feb 28, 2021 | $10.24M | Oct 27, 2021 |
| FY2021 | Nov 30, 2020 | $8.27M | Oct 27, 2021 |
| FY2021 | Aug 31, 2020 | $6.87M | Oct 27, 2021 |
| FY2021 | May 31, 2020 | $9.63M | Oct 27, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($64.72M) | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $9.95M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $9.96M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $12.48M | Oct 30, 2024 |
| FY2021 | Aug 31, 2021 | $305.0K | Oct 27, 2021 |
| FY2021 | May 31, 2021 | $3.79M | Oct 27, 2021 |
| FY2021 | Feb 28, 2021 | $3.21M | Oct 27, 2021 |
| FY2021 | Nov 30, 2020 | $2.48M | Oct 27, 2021 |
| FY2021 | Aug 31, 2020 | $2.19M | Oct 27, 2021 |
| FY2021 | May 31, 2020 | $2.94M | Oct 27, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($70.73M) | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $6.13M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $8.73M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $14.91M | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $11.25M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $11.61M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $10.65M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $10.30M | Nov 16, 2020 |
| FY2019 | Aug 31, 2017 | $8.26M | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $7.23M | Nov 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $6.88M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $5.75M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $4.50M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $3.21M | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $4.05M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $2.98M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $2.50M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $1.79M | Nov 16, 2020 |
| FY2019 | Aug 31, 2017 | $1.37M | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $1.45M | Nov 14, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $20.94M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $22.35M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $27.66M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $20.09M | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $20.57M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $16.36M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $11.80M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $9.58M | Nov 16, 2020 |
| FY2019 | Aug 31, 2017 | $8.20M | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $6.69M | Nov 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $18.13M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $13.32M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $21.86M | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $17.90M | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $19.20M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $10.91M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $11.64M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $9.29M | Nov 16, 2020 |
| FY2019 | Aug 31, 2017 | $6.88M | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $5.42M | Nov 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $713.0K | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $566.0K | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $453.0K | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | $819.0K | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $1.63M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $231.0K | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $138.0K | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $183.3K | Nov 16, 2020 |
| FY2019 | Aug 31, 2017 | $176.0K | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $39.1K | Nov 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $131.94M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $196.64M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | $186.10M | Oct 30, 2024 |
| FY2023 | Aug 31, 2022 | $188.38M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $179.98M | Oct 28, 2022 |
| FY2021 | Aug 31, 2020 | $168.42M | Oct 27, 2021 |
| FY2020 | Aug 31, 2019 | $45.20M | Nov 16, 2020 |
| FY2019 | Aug 31, 2018 | $43.28M | Nov 13, 2019 |
| FY2019 | Aug 31, 2017 | $38.51M | Nov 13, 2019 |
| FY2018 | Aug 31, 2016 | $27.81M | Nov 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $7.14M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $14.21M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | $16.07M | Oct 30, 2024 |
| FY2023 | Aug 31, 2022 | $10.13M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $14.20M | Oct 28, 2022 |
| FY2021 | Aug 31, 2020 | $12.39M | Oct 27, 2021 |
| FY2020 | Aug 31, 2019 | $7.52M | Nov 16, 2020 |
| FY2019 | Aug 31, 2018 | $11.36M | Nov 13, 2019 |
| FY2018 | Aug 31, 2017 | $12.71M | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | $5.08M | Nov 14, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $124.80M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $182.43M | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | $170.03M | Dec 1, 2025 |
| FY2025 | Aug 31, 2022 | $178.25M | Dec 1, 2025 |
| FY2023 | Aug 31, 2021 | $165.78M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $156.04M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $37.68M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $31.92M | Nov 16, 2020 |
| FY2020 | Aug 31, 2017 | $25.80M | Nov 16, 2020 |
| FY2019 | Aug 31, 2016 | $22.73M | Nov 13, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $43.72M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $96.08M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | $19.10M | Oct 30, 2024 |
| FY2024 | Aug 31, 2022 | $12.92M | Oct 30, 2024 |
| FY2023 | Aug 31, 2021 | $12.92M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $12.92M | Oct 28, 2022 |
| FY2021 | Aug 31, 2019 | $10.39M | Oct 27, 2021 |
| FY2020 | Aug 31, 2018 | $10.39M | Nov 16, 2020 |
| FY2020 | Aug 31, 2017 | $10.39M | Nov 16, 2020 |
| FY2019 | Aug 31, 2016 | $4.79M | Nov 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($34.36M) | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $30.35M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | $25.20M | Oct 30, 2024 |
| FY2023 | Aug 31, 2022 | $40.04M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $32.41M | Oct 28, 2022 |
| FY2021 | Aug 31, 2020 | $27.44M | Oct 27, 2021 |
| FY2020 | Aug 31, 2019 | $22.35M | Nov 16, 2020 |
| FY2019 | Aug 31, 2018 | $18.46M | Nov 13, 2019 |
| FY2018 | Aug 31, 2017 | $13.69M | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | $11.35M | Nov 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $30.85M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | $10.31M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | $57.52M | Oct 30, 2024 |
| FY2023 | Aug 31, 2022 | $51.57M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $36.98M | Oct 28, 2022 |
| FY2021 | Aug 31, 2020 | $49.21M | Oct 27, 2021 |
| FY2021 | Aug 31, 2019 | $11.43M | Oct 27, 2021 |
| FY2021 | Aug 31, 2018 | $9.40M | Oct 27, 2021 |
| FY2020 | Aug 31, 2017 | $6.22M | Nov 16, 2020 |
| FY2019 | Aug 31, 2016 | $8.03M | Nov 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Aug 31, 2018 | $3.33M | Nov 14, 2018 |
| FY2018 | Aug 31, 2017 | $5.74M | Nov 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | (3) | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | 0 | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | 0 | Oct 30, 2024 |
| FY2021 | Aug 31, 2021 | 0 | Oct 27, 2021 |
| FY2021 | May 31, 2021 | 0 | Oct 27, 2021 |
| FY2021 | Feb 28, 2021 | 0 | Oct 27, 2021 |
| FY2021 | Nov 30, 2020 | 0 | Oct 27, 2021 |
| FY2021 | Aug 31, 2020 | 0 | Oct 27, 2021 |
| FY2021 | May 31, 2020 | 0 | Oct 27, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | (3) | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Dec 1, 2025 |
| FY2025 | Aug 31, 2023 | 0 | Dec 1, 2025 |
| FY2024 | Aug 31, 2022 | 0 | Oct 30, 2024 |
| FY2021 | Aug 31, 2021 | 0 | Oct 27, 2021 |
| FY2021 | May 31, 2021 | 0 | Oct 27, 2021 |
| FY2021 | Feb 28, 2021 | 0 | Oct 27, 2021 |
| FY2021 | Nov 30, 2020 | 0 | Oct 27, 2021 |
| FY2021 | Aug 31, 2020 | 0 | Oct 27, 2021 |
| FY2021 | May 31, 2020 | 0 | Oct 27, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 20.14M | Dec 1, 2025 |
| FY2025 | Aug 31, 2024 | 20.05M | Dec 1, 2025 |
| FY2024 | Aug 31, 2023 | 19.94M | Oct 30, 2024 |
| FY2023 | Aug 31, 2022 | 20.26M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | 20.14M | Oct 28, 2022 |
| FY2021 | Aug 31, 2020 | 19.92M | Oct 27, 2021 |
| FY2020 | Aug 31, 2019 | 17.59M | Nov 16, 2020 |
| FY2019 | Aug 31, 2018 | 17.42M | Nov 13, 2019 |
| FY2018 | Aug 31, 2017 | 17.28M | Nov 14, 2018 |
| FY2017 | Aug 31, 2016 | 17.23M | Nov 14, 2017 |